Javascript must be enabled to continue!
LAM Cells as Potential Drivers of Senescence in Lymphangioleiomyomatosis Microenvironment
View through CrossRef
Senescence is a stress-response process characterized by the irreversible inhibition of cell proliferation, associated to the acquisition of a senescence-associated secretory phenotype (SASP), that may drive pathological conditions. Lymphangioleiomyomatosis (LAM) is a rare disease in which LAM cells, featuring the hyperactivation of the mammalian Target of Rapamycin Complex 1 (mTORC1) for the absence of tuberin expression, cause the disruption of the lung parenchyma. Considering that LAM cells secrete SASP factors and that mTOR is also a driver of senescence, we deepened the contribution of senescence in LAM cell phenotype. We firstly demonstrated that human primary tuberin-deficient LAM cells (LAM/TSC cells) have senescent features depending on mTOR hyperactivation, since their high positivity to SA-β galactosidase and to phospho-histone H2A.X are reduced by inducing tuberin expression and by inhibiting mTOR with rapamycin. Then, we demonstrated the capability of LAM/TSC cells to induce senescence. Indeed, primary lung fibroblasts (PLFs) grown in LAM/TSC conditioned medium increased the positivity to SA-β galactosidase and to phospho-histone H2A.X, as well as p21WAF1/CIP1 expression, and enhanced the mRNA expression and the secretion of the SASP component IL-8. Taken together, these data make senescence a novel field of study to understand LAM development and progression.
Title: LAM Cells as Potential Drivers of Senescence in Lymphangioleiomyomatosis Microenvironment
Description:
Senescence is a stress-response process characterized by the irreversible inhibition of cell proliferation, associated to the acquisition of a senescence-associated secretory phenotype (SASP), that may drive pathological conditions.
Lymphangioleiomyomatosis (LAM) is a rare disease in which LAM cells, featuring the hyperactivation of the mammalian Target of Rapamycin Complex 1 (mTORC1) for the absence of tuberin expression, cause the disruption of the lung parenchyma.
Considering that LAM cells secrete SASP factors and that mTOR is also a driver of senescence, we deepened the contribution of senescence in LAM cell phenotype.
We firstly demonstrated that human primary tuberin-deficient LAM cells (LAM/TSC cells) have senescent features depending on mTOR hyperactivation, since their high positivity to SA-β galactosidase and to phospho-histone H2A.
X are reduced by inducing tuberin expression and by inhibiting mTOR with rapamycin.
Then, we demonstrated the capability of LAM/TSC cells to induce senescence.
Indeed, primary lung fibroblasts (PLFs) grown in LAM/TSC conditioned medium increased the positivity to SA-β galactosidase and to phospho-histone H2A.
X, as well as p21WAF1/CIP1 expression, and enhanced the mRNA expression and the secretion of the SASP component IL-8.
Taken together, these data make senescence a novel field of study to understand LAM development and progression.
Related Results
Abstract A16: Wnt antagonist SFRP1 functions as secreted mediator of senescence
Abstract A16: Wnt antagonist SFRP1 functions as secreted mediator of senescence
Abstract
The purpose of this study was 1) to identify the mediator(s) of senescence that are secreted from senescent cells and induce senescence in an autocrine and ...
Abstract 1624: Stat1 promotes lesion growth and tumor immunity of tuberin-deficient cells in lymphangioleiomyomatosis
Abstract 1624: Stat1 promotes lesion growth and tumor immunity of tuberin-deficient cells in lymphangioleiomyomatosis
Abstract
Lymphangioleiomyomatosis (LAM) is a cystic lung disease that primarily affects women, with an estimated global prevalence of 19 per million women. LAM is ca...
Abstract 1850: Characterizing senescence response to PARP inhibition may provide opportunities for enhanced efficacy through combinations with senolytic agents
Abstract 1850: Characterizing senescence response to PARP inhibition may provide opportunities for enhanced efficacy through combinations with senolytic agents
Abstract
Background: Inhibition of poly (ADP-ribose) polymerase (PARP) is an exciting treatment strategy recently approved for prostate cancer patients with homologo...
Exploring the Role of Matrix Metalloproteinases as Biomarkers in Sporadic Lymphangioleiomyomatosis and Tuberous Sclerosis Complex. A Pilot Study
Exploring the Role of Matrix Metalloproteinases as Biomarkers in Sporadic Lymphangioleiomyomatosis and Tuberous Sclerosis Complex. A Pilot Study
Background: Lymphangioleiomyomatosis can develop in a sporadic form (S-LAM) or in women with tuberous sclerosis complex (TSC). The matrix metalloproteinases (MMPs) are extracellula...
Identification of senescence markers on cultured human corneal endothelial cells
Identification of senescence markers on cultured human corneal endothelial cells
Aims/Purpose: Corneal transplantation is currently the most frequent type of transplantation globally. However, a chronic shortage of donor corneas makes traditional methods unsust...
Identification of senescence markers on cultured human corneal endothelial cells
Identification of senescence markers on cultured human corneal endothelial cells
Aims/Purpose: Corneal transplantation is currently the most frequent type of transplantation globally. However, a chronic shortage of donor corneas makes traditional methods unsust...
Fibroblast Senescence: A Risk Factor for Remodeling, Inflammation, and Arrhythmias in the Post‐MI Heart
Fibroblast Senescence: A Risk Factor for Remodeling, Inflammation, and Arrhythmias in the Post‐MI Heart
Objectives
Cellular senescence is a stress response involving permanent replicative arrest. It is accompanied by a complex senescence‐associated secretory pheno...
Secreted Protein Combination GAPDH/S100A8/S100A9 from Human Expanded Potential Stem Cells Counteracts Mesenchymal Stem Cell Senescence
Secreted Protein Combination GAPDH/S100A8/S100A9 from Human Expanded Potential Stem Cells Counteracts Mesenchymal Stem Cell Senescence
Abstract
Background
Human mesenchymal stem cells (hMSCs) remain the most clinically advanced adult stem cell source; however, their therapeutic potential is limite...

